Brainomix's AWARD-WINNING AI TECHNOLOGY
Brainomix, a leader in artificial intelligence (AI) imaging solutions, has made significant strides in the healthcare sector, showcasing its prowess with transformative technology. Recently, the company was honored with two prestigious awards, underscoring the profound impact of its software on patient care and treatment rates.
Recognition in Healthtech Innovation
The LSX European Lifestars Award recognized Brainomix as the "Healthtech Company of the Year". Add to that the accolade for the "Most Transformative Healthtech Company of the Year" bestowed by OBN, and it's clear that Brainomix is setting benchmarks in healthcare innovations.
A Year of Notable Achievements
The journey leading to these awards is commendable. In the past year, Brainomix achieved remarkable endorsements, including recognition from the National Institute for Health & Care Excellence (NICE) and several FDA clearances related to stroke management and lung fibrosis. These milestones have not only boosted the company’s credibility but have also facilitated its expansion into new markets.
Transformative Impact on Stroke Care
Brainomix's flagship product, Brainomix 360 Stroke, demonstrated remarkable efficacy as evidenced by a study presented at the European Stroke Organisation Conference. The findings revealed an impressive 50% increase in patients receiving mechanical thrombectomy—a critical procedure for stroke treatment.
Success on a Global Scale
The AI technology's advantages extend beyond individual hospitals; it has been integrated nationwide in multiple countries. In regions like Wales and Hungary, Brainomix 360 Stroke is operational in all stroke centers, capable of delivering substantial improvements in treatment rates.
Voices from the Field
Real-world evaluations from healthcare institutions share the technology's positive outcomes. In Hungary, where the system is utilized across 28 sites, thrombectomy rates surged over 50%. According to leading medical professionals like Prof István Szikora, the technology has significantly advanced stroke care in Hungary.
Similarly, in Wales, the adoption of the Brainomix platform resulted in a notable increase of over 44% in thrombectomies performed. Clinicians, including Dr. Shakeel Ahmad, lauded the platform’s ability to convert simple brain scans into vital information. This has significantly improved decision-making quality, resulting in better health outcomes for stroke patients.
About Brainomix
Founded as a spin-out from the University of Oxford, Brainomix is on a mission to revolutionize precision medicine through AI-powered solutions. With offices in the UK, Ireland, and the USA, the company operates in over 30 countries, equipped with innovative imaging biomarkers that have been incorporated into clinical practice globally. The Brainomix 360 stroke platform stands as a testament to their commitment, delivering enhanced diagnostic capabilities and better outcomes for patients suffering from strokes and lung fibrosis.
Frequently Asked Questions
What is Brainomix recognized for?
Brainomix is renowned for its groundbreaking AI imaging technology that enhances treatment rates for stroke and lung fibrosis.
What awards did Brainomix receive recently?
The company received the LSX European Lifestars Award for "Healthtech Company of the Year" and the "Most Transformative Healthtech Company of the Year" from OBN.
How has Brainomix technology affected stroke treatment?
Its AI-driven platform has led to a significant increase in the number of patients receiving crucial procedures like mechanical thrombectomy.
Where is Brainomix's technology deployed?
Brainomix technology is utilized across multiple countries including Hungary and Wales, leading to increased treatment rates in both regions.
What is the goal of Brainomix?
The company aims to facilitate faster diagnoses and expand access to life-saving treatments through innovative AI solutions.
